Article
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.
Blood cancer journal - 29 Apr 2024
Medina-Herrera A, Vazquez I, Cuenca I, Rosa-Rosa J M, Ariceta B, Jimenez C, Fernandez-Mercado M, Larrayoz M J, Gutierrez N C, Fernandez-Guijarro M, Gonzalez-Calle V, Rodriguez-Otero P, Oriol A, Rosiñol L, Alegre A, Escalante F, De La Rubia J, Teruel A I, De Arriba F, Hernandez M T, Lopez-Jimenez J, Ocio E M, Puig N, Paiva B, Lahuerta J J, Bladé J, San Miguel J F, Mateos M V, Martinez-Lopez J, Calasanz M J, Garcia-Sanz R
Abstract excerpt
Smoldering multiple myeloma (SMM) precedes multiple myeloma (MM). The risk of progression of SMM patients is not uniform, thus different progression-risk models have been developed, although they are mainly based on clinical parameters. Recently, genomic predictors of progression have been defined for untreated SMM. However, the usefulness of such markers in the context of clinical trials evaluating upfront...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.